Carotuximab-MMAE is an antibody-drug conjugate (ADC) targeting Endoglin / CD105. Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway.
Purity:
>95%, Endotoxin < 1 EU/µg
* VAT and and shipping costs not included. Errors and price changes excepted
